(function(){var loadHandler=window['sl_{B169E353-1691-4AFC-B51D-F07AF60FC333}'];loadHandler&&loadHandler(5, '<div id="spr0_58785b3f"><div id="spr1_58785b3f" class="kern slide"><img id="img3_58785b3f" src="data/img1.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_58785b3f" class="kern slide"><img id="img0_58785b3f" src="data/img3.png" width="721.48" height="100.8" alt="" style="left:-1.48px;"/><div id="svg1_58785b3f" style="left:-1.48px;top:99.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#c76c02" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><div id="svg2_58785b3f" style="left:-1.48px;top:0.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#2e3546" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><img id="img1_58785b3f" src="data/img8.png" width="721.48" height="43.101" alt="" style="top:496.899px;"/><div id="spr3_58785b3f" style="left:657.715px;top:499.855px;"><img id="img2_58785b3f" src="data/img9.png" width="56" height="36" alt="CHRC logo_with text.psd" style="left:-0.105px;top:-0.177px;"/></div><div id="spr4_58785b3f" style="left:0px;top:7.56px;"><div style="width:0px;"><span id="txt0_58785b3f" data-width="385.505859" style="left:167.38px;top:5.272px;">ODYSSEY Outcomes Study</span></div><div style="width:0px;"><span id="txt1_58785b3f" data-width="155.010635" style="left:287.81px;top:48.171px;">Alirocumab</span></div></div><div id="spr5_58785b3f" style="left:6.496px;top:508.59px;"><div style="width:0px;"><span id="txt2_58785b3f" class="nokern" data-width="182.583984" style="left:7.2px;top:4.096px;">Schwartz GG, et al. N Engl J Med. 2018:379:2097-2107</span></div></div><div id="spr6_58785b3f" style="left:4.821px;top:118.893px;"><div style="width:0px;"><span id="txt3_58785b3f" class="nokern relpos" style="left:7.2px;top:5.523px;"></span><span id="txt4_58785b3f" class="relpos" data-width="569.789063" style="left:23.22px;top:4.715px;">18,924 patients with ACS within prior year, not stable ASCVD</span></div><div style="width:0px;"><span id="txt5_58785b3f" class="nokern relpos" style="left:7.2px;top:63.123px;"></span><span id="txt6_58785b3f" class="relpos" data-width="463.769531" style="left:23.22px;top:62.315px;">2 to 16 weeks optimized atorvastatin/rosuvastatin</span></div><div style="width:0px;"><span id="txt7_58785b3f" class="nokern relpos" style="left:43.2px;top:91.102px;">─</span><span id="txt8_58785b3f" class="relpos" data-width="594.482422" style="left:55.591px;top:91.102px;">If LDL-C ≥ 1.8 mmol/L, non-HDL-C ≥ 2.6 mmol/L, or apoB ≥ 0.8 g/L patients were</span></div><div style="width:0px;"><span id="txt9_58785b3f" data-width="108.496094" style="left:70.2px;top:115.102px;">randomized to:</span></div><div style="width:0px;"><span id="txt10_58785b3f" class="nokern relpos" style="left:79.2px;top:139.405px;"></span><span id="txt11_58785b3f" class="relpos" data-width="305.208984" style="left:97.965px;top:138.992px;">Alirocumab 75 mg every two weeks or placebo</span></div><div style="width:0px;"><span id="txt12_58785b3f" class="nokern relpos" style="left:7.2px;top:183.123px;"></span><span id="txt13_58785b3f" class="relpos" data-width="310.582031" style="left:23.22px;top:182.315px;">Titration target: 0.6 to 1.3 mmol/L</span></div><div style="width:0px;"><span id="txt14_58785b3f" class="nokern relpos" style="left:43.2px;top:211.102px;">─</span><span id="txt15_58785b3f" class="relpos" data-width="166.845703" style="left:55.591px;top:211.102px;">If LDL-C ≥ 1.3 mmol/L </span><span id="txt16_58785b3f" class="relpos" style="left:55.586px;top:211.561px;"></span><span id="txt17_58785b3f" class="relpos" data-width="344.628906" style="left:55.581px;top:211.102px;"> alirocumab uptitrated to 150 mg every 2 weeks</span></div><div style="width:0px;"><span id="txt18_58785b3f" class="nokern relpos" style="left:43.2px;top:235.102px;">─</span><span id="txt19_58785b3f" class="relpos" data-width="165.449219" style="left:55.591px;top:235.102px;">If LDL-C &lt; 0.4 mmol/L </span><span id="txt20_58785b3f" class="relpos" style="left:55.586px;top:235.561px;"></span><span id="txt21_58785b3f" class="relpos" data-width="148.623047" style="left:55.581px;top:235.102px;"> switched to placebo</span></div><div style="width:0px;"><span id="txt22_58785b3f" class="nokern relpos" style="left:7.2px;top:283.923px;"></span><span id="txt23_58785b3f" class="relpos" data-width="250.476563" style="left:23.22px;top:283.115px;">Median follow-up 2.8 years</span></div><div style="width:0px;"><span id="txt24_58785b3f" class="nokern relpos" style="left:43.2px;top:311.902px;">─</span><span id="txt25_58785b3f" class="relpos" data-width="496.826172" style="left:55.591px;top:311.902px;">On-treatment LDL-C: alirocumab 1.4 mmol/L vs. placebo 2.6 mmol/L</span></div></div></div></div>');})();